Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Follicular lymphoma at diagnosis, treated in first line with immunochemotherapy Data Acces Comitee

ABSTRACT: Data Access Committee EGAC00001002912

PROVIDER: EGAC00001002912 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Similar Datasets

Follicular lymphoma at diagnosis, treated in first line with immunochemotherapy

Project description:We performed targeted NGS in Follicular lymphoma samples at diagnosis. Explored clinico-genetic correlations and assessed four clinical or clinicogenetic risk models (FLIPI, FLIPI-2, PRIMA-IP or m7-FLIPI-molecular score) in patients with symptomatic FL who received frontline immunochemotherapy. Out of 191 patients with FL grade 1-3a, 109 were successfully genotyped. Treatment consisted on rituximab (R) plus CVP/CHOP (72.5%) or R-bendamustine (R-B) (27.5%).

| EGAS00001006674 | EGA

Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy.

Project description: Not available

| S-EPMC10173729 | biostudies-literature

Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy.

Project description: Not available

| S-EPMC6595360 | biostudies-literature

Unmet needs in the first-line treatment of follicular lymphoma.

Project description: Not available

| S-EPMC5834060 | biostudies-literature

The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma.

Project description: Not available

| S-EPMC7317728 | biostudies-literature

Prospects in the management of patients with follicular lymphoma beyond first-line therapy.

Project description: Not available

| S-EPMC8719064 | biostudies-literature

Clinicogenetic Risk Prognostication for First-Line Treatment of Symptomatic Follicular Lymphoma

Project description:Background: Follicular lymphoma (FL) is an indolent malignancy of germinal center B cells with highly variable patient outcomes. Recently, a 23-gene predictor score was proposed for predicting progression-free survival. In the past, we had shown that the m7-FLIPI, a clinico-genetic risk model, allows to improve patient stratification compared to clinical risk models alone. The multitude of prognostic tools in FL raises the question whether they identify common biology. Methods: In this study, we applied a modified risk score (MRS) to an independent gene-expression dataset of FL patients treated with rituximab in combination with chemotherapy. Results: Using supervised and unsupervised approaches, we showed that the MRS identifies patient groups with diverging outcomes in our dataset. In addition, using gene set enrichment and network identification, we discovered associations between the MRS, the m7-FLIPI, EZH2 mutation status and FOXP1 expression. Conclusions: Our findings lend support to expression of dark-zone related genes as a key determinant of poor outcome following rituximab and chemotherapy.

2019-02-19 | GSE119214 | GEO

Comparative analysis of rituximab or obinutuzumab combined with CHOP in first-line treatment of follicular lymphoma.

Project description: Not available

| S-EPMC9255466 | biostudies-literature

Immune Signatures Identify Patient Subsets Deriving Long-Term Benefit From First-Line Rituximab in Follicular Lymphoma.

Project description: Not available

| S-EPMC11804214 | biostudies-literature

Exploratory Study to Evaluate the Impact of Interim PET/CT Assessment in First-Line Follicular Lymphoma.

Project description: Not available

| S-EPMC11988115 | biostudies-literature